KRAS and non-small cell lung carcinoma: TVB-2640 is a potent and reversible inhibitor of FASN and has been validated in a variety of tumor cell lines, including KRAS-mutant non-small cell lung cancer (NSCLC), colon cancer, advanced HER2 breast cancer, and glioblastoma, as well as in clinical studies 85.